These data significantly de-risk ivonescimab's clinical profile and support its potential to become a new standard in 1L NSCLC. Key catalysts ahead: HARMONi BLA PDUFA on November 14, 2026, and upcoming HARMONi-3 data readouts (SQ PFS/interim OS in 2H26, nSQ PFS in 1H27). Monitor for FDA advisory committee meeting and potential accelerated approval path.
Price Chart
Executive Summary
Summit Therapeutics announced positive Phase III HARMONi-6 overall survival results for ivonescimab in first-line squamous NSCLC (HR 0.66, p=0.0017 vs tislelizumab+chemo) and encouraging Phase II CRC data (70.8% ORR, 100% DCR) at ASCO 2026. These data further validate ivonescimab's differentiated PD-1/VEGF bispecific mechanism and support its potential as a new standard of care in NSCLC, with a BLA PDUFA date of November 14, 2026 for the HARMONi trial in EGFR-mutant NSCLC.
Key Facts
- HARMONi-6 Phase III: ivonescimab+chemo reduced risk of death by 34% vs tislelizumab+chemo (HR 0.66, 95% CI 0.50-0.87, p=0.0017) in 1L squamous NSCLC
- Median OS: 27.89 months (ivonescimab) vs 23.69 months (tislelizumab); 24-month OS rates 64.7% vs 48.6%
- First Phase III trial to show statistically significant OS benefit over an anti-PD-(L)1+chemo regimen in 1L NSCLC
- Phase II CRC (AK112-206): 70.8% ORR and 100% DCR with ivonescimab+mFOLFOX6 in 1L MSS mCRC; 9-month PFS rate 76.1% at 20 mg/kg dose
- BLA for ivonescimab in EGFR-mutant NSCLC (HARMONi trial) accepted by FDA with PDUFA date of November 14, 2026
- Results published simultaneously in The Lancet; presented at ASCO 2026 Plenary Session
- Safety profile manageable: Grade 3 TRAEs 69.2% (ivonescimab) vs 58.9% (tislelizumab); similar discontinuation rates (5.3% vs 4.5%)
Financial Impact
No financial figures provided in filing. Ivonescimab is pre-revenue in Summit's license territories; potential $15B+ revenue opportunity by 2033 per company estimates (not from filing).
Risk Factors
- HARMONi-6 is a single-region China study by partner Akeso; results may not fully replicate in global HARMONi-3 trial
- Higher Grade 3 TRAE rate (69.2% vs 58.9%) and VEGF-related hemorrhage (2.6% Grade 3+ vs 0.8%) warrant monitoring
- Ivonescimab not yet approved in any Summit license territory; regulatory and commercial execution risks remain
- Competitive landscape includes established PD-1 inhibitors and emerging bispecifics
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001599298-26-000043 |
| Document: a20260601ascoupdatecalld.htm | 0001599298-26-000043 |
| Document: ivonescimab-withxchemoth.htm | 0001599298-26-000043 |
| Document: encouraging-globalxphase.htm | 0001599298-26-000043 |
| Document: 0001599298-26-000043-index-headers.html | 0001599298-26-000043 |
| Document: 0001599298-26-000043-index.html | 0001599298-26-000043 |
| Document: 0001599298-26-000043.txt | 0001599298-26-000043 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 8-K | $17.40 $17.85 | ▲ +2.59% | ▲ +1.77% | $16.75 (−3.71%) |
Sep 14, 2026 18d ago | 8-K | $18.42 $16.90 | ▼ −8.25% | ▼ −8.36% | $16.75 (−9.04%) |
Sep 3, 2026 29d ago | 8-K | $17.13 $17.55 | ▲ +2.45% | ▲ +3.60% | $16.75 (−2.19%) |
Aug 26, 2026 5w ago | 8-K | $14.23 $14.60 | ▲ +2.60% | ▲ +2.72% | $16.75 (+17.74%) |
Aug 5, 2026 8w ago | 8-K | $13.53 $15.10 | ▲ +11.60% | ▲ +11.25% | $16.75 (+23.84%) |
Jul 22, 2026 10w ago | 8-K | $14.74 $12.80 | ▼ −13.16% | ▼ −10.76% | $16.75 (+13.67%) |
Jun 12, 2026 16w ago | Insider Cluster | $14.01 $13.75 | ▼ −1.86% | ▼ −2.53% | $16.75 (+19.59%) |
Jun 12, 2026 16w ago | Institutional Cluster | $14.01 $13.75 | ▼ −1.86% | ▼ −2.53% | $16.75 (+19.59%) |
Jun 11, 2026 16w ago | Institutional Cluster | $13.08 $14.07 | ▲ +7.57% | ▲ +7.14% | $16.75 (+28.10%) |
Jun 9, 2026 16w ago | S-3ASR | $13.05 $13.88 | ▼ −6.36% | ▼ −2.93% | $16.75 (−28.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access